MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1256.69%
Quick Ratio
1256.69%
Cash Ratio
138.83%
Debt to Asset Ratio
17.03%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities - short te...
    • Cash and cash equivalents
    • Marketable securities - long ter...
    • Others
Liabilities Breakdown
    • Common shares, no par value unli...
    • Accumulated deficit
    • Additional paid-in capital
    • Others
Balance Sheets
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Cash and cash equivalents
29,827
36,613
50,152
32,623
Marketable securities - short term
228,638
239,335
143,584
169,290
Restricted investments
75
74
79
72
Investment tax credits receivable
822
1,197
927
709
Prepaid and other current assets
10,638
11,997
6,649
8,618
Total current assets
270,000
289,216
201,391
211,312
Marketable securities - long term
26,709
36,601
8,522
23,011
Property and equipment, net
2,335
2,441
2,477
1,879
Operating lease right of use asset
7,105
7,470
7,716
7,969
Other assets
1,375
1,385
1,362
1,379
Total assets
307,524
337,113
221,468
245,550
Accounts payable
1,793
2,435
6,688
2,384
Accrued expenses and other current liabilities
17,212
19,668
15,275
11,117
Operating lease liabilities, current
2,287
2,318
2,014
1,527
Current portion of note payable
193
188
8,002
5,412
Total current liabilities
21,485
24,609
31,979
20,440
Note payable, net of current portion
24,910
24,736
15,324
17,706
Operating lease liabilities, net of current portion
5,961
6,222
6,455
6,732
Liabilities, total
52,356
55,567
53,758
44,878
Common shares, no par value unlimited shares authorized, 66,989,466 and 52,018,658 shares issued and outstanding as of april 30, 2026 and october 31, 2025, respectively
631,995
631,992
513,281
510,164
Additional paid-in capital
56,325
52,180
27,349
25,869
Accumulated other comprehensive loss
-1,141
-842
-888
-1,209
Accumulated deficit
-432,011
-401,784
-372,032
-334,152
Total shareholder's equity
255,168
281,546
167,710
200,672
Total liabilities and shareholders' equity
307,524
337,113
221,468
245,550
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities -short term$228,638K Cash and cashequivalents$29,827K Prepaid and othercurrent assets$10,638K Investment tax creditsreceivable$822K Restricted investments$75K Total current assets$270,000K Marketable securities -long term$26,709K Operating lease right ofuse asset$7,105K Property and equipment,net$2,335K Other assets$1,375K Total assets$307,524K Total liabilities andshareholders' equity$307,524K Total shareholder'sequity$255,168K Liabilities, total$52,356K Accumulated deficit-$432,011K Accumulated othercomprehensive loss-$1,141K Common shares, no parvalue unlimited...$631,995K Note payable, net ofcurrent portion$24,910K Total currentliabilities$21,485K Operating leaseliabilities, net of current...$5,961K Additional paid-in capital$56,325K Accrued expenses andother current...$17,212K Operating leaseliabilities, current$2,287K Accounts payable$1,793K Current portion of notepayable$193K

enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Inc. (ENGN)